promising results for axitinib and pembrolizumab in advanced renal cell cancer
Published 5 years ago • 2K plays • Length 3:30Download video MP4
Download video MP3
Similar videos
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
1:06
exciting potential of pembrolizumab combined with axitinib for kidney cancer
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
0:49
clear: lenvatinib and pembrolizumab in advanced renal cell carcinoma
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
3:10
keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
-
1:44
assessing lenvatinib with pembrolizumab in advanced renal cell carcinoma
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
4:25
kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
-
1:29
phase i/ii study of nivolumab and axitinib for advanced rcc
-
0:47
avelumab plus axitinib shows good efficacy for os and pfs in arcc patients
-
0:59
combining lenvatinib & pembrolizumab for non-clear cell rcc: keynote-b61 study rationale
-
9:23
javelin renal 101: avelumab plus axitinib improve pfs for advanced renal cell cancer
-
1:20
promising results of cabozantinib plus nivolumab in non-clear cell rcc
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc